DESVENLAFAXINE

N/A

Manufactured by Actavis Pharma, Inc.

6,688 FDA adverse event reports analyzed

Last updated: 2026-04-15

About DESVENLAFAXINE

DESVENLAFAXINE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Actavis Pharma, Inc.. The most commonly reported adverse reactions for DESVENLAFAXINE include DRUG INEFFECTIVE, TOXICITY TO VARIOUS AGENTS, OFF LABEL USE, NAUSEA, COMPLETED SUICIDE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for DESVENLAFAXINE.

Top Adverse Reactions

DRUG INEFFECTIVE278 reports
TOXICITY TO VARIOUS AGENTS233 reports
OFF LABEL USE208 reports
NAUSEA206 reports
COMPLETED SUICIDE186 reports
ANXIETY180 reports
OVERDOSE174 reports
FATIGUE166 reports
DRUG INTERACTION164 reports
DEPRESSION161 reports
HEADACHE159 reports
DIZZINESS133 reports
PAIN117 reports
SEROTONIN SYNDROME115 reports
INSOMNIA114 reports
SUICIDAL IDEATION109 reports
DYSPNOEA108 reports
PRODUCT DOSE OMISSION ISSUE103 reports
CONDITION AGGRAVATED94 reports
DIARRHOEA94 reports
VOMITING94 reports
PRODUCT USE IN UNAPPROVED INDICATION81 reports
FALL79 reports
PRURITUS79 reports
PNEUMONIA78 reports
WEIGHT INCREASED76 reports
FEELING ABNORMAL75 reports
ASTHENIA73 reports
MALAISE72 reports
RASH72 reports
ARTHRALGIA70 reports
COVID 1969 reports
CONSTIPATION65 reports
HYPERHIDROSIS64 reports
SOMNOLENCE62 reports
SEIZURE58 reports
SUICIDE ATTEMPT57 reports
TREMOR57 reports
DECREASED APPETITE54 reports
COUGH53 reports
DEATH52 reports
WITHDRAWAL SYNDROME52 reports
CONFUSIONAL STATE51 reports
BACK PAIN48 reports
INTENTIONAL OVERDOSE48 reports
PRODUCT USE ISSUE48 reports
MIGRAINE47 reports
ABDOMINAL PAIN46 reports
PAIN IN EXTREMITY46 reports
PRODUCT SUBSTITUTION ISSUE45 reports
HYPERTENSION44 reports
PARAESTHESIA44 reports
URTICARIA44 reports
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION42 reports
MEMORY IMPAIRMENT42 reports
PANIC ATTACK42 reports
PYREXIA42 reports
WEIGHT DECREASED41 reports
AGITATION40 reports
DRUG WITHDRAWAL SYNDROME40 reports
HYPOTENSION40 reports
ALOPECIA39 reports
ABDOMINAL PAIN UPPER38 reports
DRUG ABUSE38 reports
NASOPHARYNGITIS38 reports
VISION BLURRED38 reports
SLEEP DISORDER37 reports
ILLNESS36 reports
URINARY TRACT INFECTION35 reports
TACHYCARDIA34 reports
DEHYDRATION33 reports
DRUG INTOLERANCE33 reports
DRY MOUTH33 reports
HYPOAESTHESIA33 reports
BLOOD PRESSURE INCREASED32 reports
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION32 reports
GAIT DISTURBANCE32 reports
IRRITABILITY32 reports
TREATMENT NONCOMPLIANCE32 reports
DERMATITIS ATOPIC31 reports
HEART RATE INCREASED31 reports
HYPERSENSITIVITY31 reports
INJECTION SITE PAIN31 reports
PERIPHERAL SWELLING31 reports
PSORIASIS31 reports
SINUSITIS31 reports
ABDOMINAL DISCOMFORT30 reports
ABDOMINAL DISTENSION30 reports
CARDIAC ARREST30 reports
CHEST PAIN30 reports
DRUG HYPERSENSITIVITY30 reports
DYSPEPSIA30 reports
HOT FLUSH30 reports
HYPONATRAEMIA30 reports
CHILLS29 reports
INTENTIONAL PRODUCT USE ISSUE29 reports
MYALGIA29 reports
TREATMENT FAILURE29 reports
HALLUCINATION28 reports
NERVOUSNESS28 reports

Report Outcomes

Out of 3,265 classified reports for DESVENLAFAXINE:

Serious 69.5%Non-Serious 30.5%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female2,067 (71.7%)
Male804 (27.9%)
Unknown10 (0.3%)

Reports by Age

Age 5365 reports
Age 3963 reports
Age 4462 reports
Age 5162 reports
Age 4961 reports
Age 5056 reports
Age 3555 reports
Age 4155 reports
Age 6354 reports
Age 5253 reports
Age 6052 reports
Age 5951 reports
Age 6845 reports
Age 5444 reports
Age 6644 reports
Age 4543 reports
Age 6943 reports
Age 4042 reports
Age 6242 reports
Age 6441 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with DESVENLAFAXINE?

This profile reflects 6,688 FDA FAERS reports that mention DESVENLAFAXINE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for DESVENLAFAXINE?

Frequently reported terms in FAERS include DRUG INEFFECTIVE, TOXICITY TO VARIOUS AGENTS, OFF LABEL USE, NAUSEA, COMPLETED SUICIDE, ANXIETY. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures DESVENLAFAXINE?

Labeling and FAERS entries often list Actavis Pharma, Inc. in connection with DESVENLAFAXINE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.